CTOs on the Move


 
Genexa is the world`s first and only clean medicine company and was recognized in 2022 by Fast Company as the no. 1 Most Innovative Company in Wellness. We were founded in 2016 by two dads who believed medicine should only have the active ingredients you need, and not the artificial fillers you don`t. It`s medicine made clean, because that`s what people deserve. Our headquarters is located in Atlanta, where we strive to put people over everything
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.genexa.com
  • 1510 Ellsworth Industrial Boulevard NW Building Two, Suite 10
    Atlanta, GA USA 30318
  • Phone: 855.436.3921

Executives

Name Title Contact Details

Similar Companies

Pathalys

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.

BioScrip

BioScrip is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardiocore Lab, Inc.

Cardiocore Lab, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Assertio Therapeutics

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company.

Forma Therapeutics

At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications.